Sutro Biopharma Inc. (STRO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Sutro Biopharma Inc. (STRO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.81

0.09 (5.23%)

At close: Jan 15, 2025, 11:15 AM

undefined% (undefined)

Bid	1.8
Market Cap	149.25M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.55
PE Ratio (ttm)	-1.17
Forward PE	n/a
Analyst	Buy

Ask	1.81
Volume	292,591
Avg. Volume (20D)	962,129
Open	1.78
Previous Close	1.72
Day's Range	1.75 - 1.84
52-Week Range	1.67 - 6.13
Beta	undefined

About STRO

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-H...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 27, 2018

Employees 302

Stock Exchange NASDAQ

Ticker Symbol STRO

Website https://www.sutrobio.com

Analyst Forecast

According to 7 analyst ratings, the average rating for STRO stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 562.98% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Sutro Biopharma Inc. is scheduled to release its earnings on Mar 24, 2025, during market hours.
Analysts project revenue of $12.18M, reflecting a -89.29% YoY shrinking and earnings per share of -0.95, making a -282.69% decrease YoY.

Why Price Moved

2 months ago · Source

-12.88%

Sutro Biopharma shares are trading lower after the... Unlock content with Pro Subscription

4 months ago · Source

-17.78%

Sutro Biopharma shares are trading lower. The company announced updated data from the ongoing Phase 1b study of luveltamab tazevibulin in combination with bevacizumab for patients with epithelial ovarian cancer in a poster presentation at the 2024 ESMO Congress.

News

1 week ago · seekingalpha.com

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promisin...

1 month ago · zacks.com

Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know

Sutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.81 per share a year ago.